David Feltquate Head of Early Clinical Development at BRISTOL-MYERS SQUIBB discusses the the phase 1b/2 open-label study which will explore the combination of standard chemotherapy and two immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40 in pancreatic cancer. The two agents are APX005M & Nivolumab and the trial is unique in that four institutions, The Parker Institute for Cancer Immunotherapy, the Cancer Research Institute, Bristol-Myers Squibb and Apexigen, are combining their efforts to speed the trial and results.
CD40 Antibody APX005M, Nivolumab & Chemotherapy Phase 1b 2 Study to Explore Combo Chemotherapy and 2 Immunotherapy Agents
